Nitric oxide production is reduced in patients with chronic renal failure

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 5, 1999, Pages 1168-1172

  Wever, Robert ^d   Boer, Peter ^c   Hijmering, Michel ^a   Stroes, Erik ^d   Verhaar, Marianne ^d   Kastelein, John ^b   Versluis, Kees ^d   Lagerwerf, Fija ^d   Van Rijn, Herman ^d   Koomans, Hein ^d   Rabelink, Ton ^d  

^a U Gene Clinical Pharmacology Unit   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d NONE

Author keywords

Atherosclerosis; Chronic renal failure; Endothelium; Hypercholesterolemia; Nitric oxide

Indexed keywords

NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEGRADATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; UREA CYCLE;

EID: 0032962736     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.5.1168     Document Type: Article

References (55)

1. De Lemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol. 1996;7:2044-2054.
2. Wever RMF, Lüscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation. 1998;97: 108-112.
3. Creager M, Cooke JP, Mendelsohn ME. Impaired vasodilatation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.
4. Chowienczyk PJ, Watts GF, Cockroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolemia. Lancet. 1992;340:1430-1432.
5. Stroes ES, Koomans HA, De Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet. 1995;346:467-471.
6. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to lipoprotein (a) level. J Clin Invest. 1994;93:50-55.
7. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, Bunce T, Dorado B, Deanfield JE, Rees L. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 1997;52:468-472.
8. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
9. McAllister Rj, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasmas of patients with end-stage renal failure. Nephrol Dial Transplant. 1996;11: 2449-2452.
10. Reyes AA, Purkerson ML, Karl I, Klahr S. Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis. 1992;20:168-176.
11. Bouby N, Hassler C, Parvy P, Bankir L. Renal synthesis of arginine in chronic renal failure: in vivo and in vitro studies in rats with 5/6 nephrectomy. Kidney Int. 1993;44:676-683.
12. Bergström J, Alvestrand A, Fürst P. Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition. Kidney Int. 1990;38:108-114.
13. Haklar G, Yegenaga I, Yalcin AS. Evaluation of oxidant stress in chronic hemodialysis patients: use of different parameters. Clin Chim Acta. 1995; 234:109-114.
14. Durak I, Akyol O, Basesme E, Canbolat O, Kavutcu M. Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron. 1994;66:76-80.
15. Loughry CM, Young IS, Lightbody JH, McMaster C, McNamee PT, Trimble ER. Oxidative stress in hemodialysis. QJM. 1994;87:679-683.
16. Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell. 1994;78:927-930.
17. 15N]citrulline labeling. Proc Natl Acad Sci U S A. 1996;93:11460-11465.
18. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson E, Deanfield JE, Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;8:2149-2155.
19. Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Lust H, Olschewski M, Drexler H. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation. 1996;93:1346-1353.
20. 15N]citrulline enrichment in human plasma using high-performance liquid chromatography-mass spectrometry. Anal Biochem. 1998;257:45-52.
21. Cooke JP, Tsao PS. Is NO an anti-atherogenic molecule? Arterioscler Thromb. 1994;14:653-655.
22. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int. 1997;51:1678-1695.
23. Wilcoc JN, Subramanian RR, Tracey WR, Pollock JS, Harrison DG, Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscl Thromb Vasc Biol. 1997; 17:2479-2488.
24. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308-318.
25. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995;6:121-125.
26. Janssen MJ, van Guldener C, de Jong GM, van den Berg M, Stehouwer CD, Donker AJM. Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab. 1996;22:110-114.
27. Kuroda M, Asaka S, Tofuku Y, Takeda R. Serum antioxidant activity in uremic patients. Nephron. 1985;41:293-298.
28. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia V, Nguyen AT, Thevenin , Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med. 1996;21:845-853.
29. Lucchi I, Banni S, Botti B, Cappelli G, Medici G, Melis MP, Tomasi A, Vannini V, Lusvarghi E. Conjugated diene fatty acids in patients with chronic renal failure: evidence of increased lipid peroxidation? Nephron. 1993;65:401-409.
30. Freeman JE, Kuo WY, Drenger B, Barnett TN, Levine MA, Flavahan NA. Analysis of lysophosphatidylcholine-induced endothelial dysfunction. J Cardiovasc Pharmacol. 1996;28:345-352.
31. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 1995;270:319-324.
32. Bode-Böger SM, Böger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun. 1996;219:598-603.
33. Cooke JP, Tsao PS. Arginine: a new therapy for atherosclerosis? Circulation. 1997;95:311-312.
34. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest. 1996;97:1989-1994.
35. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
36. Ohara Y, Peterson TE, Sayegh HS, Subramanian RR, Wilcox JN, Harrison DG. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation. 1995; 92:898-903.
37. Pritchard KA, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 1995;77:510-518.
38. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A. 1996;93:8745-8749.
39. Wever RMF, van Dam T, van Rijn HJM, de Groot F, Rabelink TJ. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun. 1997;237:340-344.
40. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271:C1424-C1437.
41. Cardillo C, Kilcoyne CM, Cannon RO, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997;30:57-63.
42. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
43. Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation. 1997;95:2617-2622.
44. Reilly M, Delanty N, Lawson JA, Fitzgerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996;94:19-25.
45. McVeigh, GE, Lemay L, Morgan D, Cohn JN. Effects of long-term cigarette smoking on endothelium-dependent responses in humans. Am J Cardiol. 1996;78:668-672.
46. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 1996;94:6-9.
47. 2]arginine: application to the response to vaccination. Am J Physiol. 1997;272:R1888-R1896.
48. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997;17:2479-2488.
49. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ. Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol. 1998;274:F642-F649.
50. Furusu A, Miyazaki M, Abe K, Tsukasaki S, Shioshita K, Sasaki O, Miyazaki K, Ozono Y, Koji T, Harada T, Sakai H, Kohno S. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int. 1998;53:1760-1768.
51. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Corna D, Zoja C, Cavallotti D, Remuzzi G. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int. 1998;52: 171-181.
52. Koglin J, Glysing-Jensen T, Mudgett JS, and Russell ME. Exacerbated transplant atherosclerosis in inducible nitric oxide-deficient mice. Circulation. 1998;97:2059-2065.
53. Yan Z, Hansson GK. Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. Circ Res. 1998;82:21-29.
54. Shears LL, Kawaharada N, Tzeng E, Billiar TR, Watkins SC, Kovesdi I, Lizonova A, Pham SM. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest. 1997;100: 2035-2042.
55. Tzeng E, Shears LL 2nd, Robbins PD, Pitt BR, Geller DA, Watkins SC, Simmons RL, Billiar TR. Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. Mol Med. 1996;2:211-225.